Amgen Inc.
(AMGN)
Add Watchlist
312.47 USD +0.56
Closed: 17 May, 3:55 pm
Symbol AMGN
Market Cap 167.6B
Price 312.47
Open 315.28
52-wk High 329.72
50 Day Avg 280.35
Earnings Announcement 2024-08-01
Website https://www.amgen.com
Name Amgen Inc.
Shares Outstanding 536,434,999
Change % -0.7149%
Low 310.38
52-wk Low 211.71
200 Day Avg 277.55
Last Dividend 9.00
Exchange NASDAQ
Volume 1,971,450
Previous Close 314.72
High 315.28
EPS 6.99
PE 44.70
Avg Volume 2,784,132
CUSIP 031162100
Amgen Inc. Outlook
Description Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Currency USD
ISIN US0311621009
Industry Drug Manufacturers - General
Changes -2.25
CUSIP 031162100
Range 211.71 - 329.72
Beta 0.60
CIK 0000318154

Amgen Inc. News

17-May-2024 12:51 PM

Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC

Amgen's (AMGN) Imdelltra is the first DLL3-targeting BiTE therapy that activates the patient's own T cells to attack DLL3-expressing tumor cells.

17-May-2024 11:06 AM

4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly

Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.

17-May-2024 8:24 AM

Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk

Wegovy and Zepbound are two of the hottest GLP-1 drugs available on the market right now. The field, however, could become more crowded as more companies develop rival treatments.

16-May-2024 8:21 PM

Amgen gets FDA approval for small-cell lung-cancer treatment

Amgen AMGN, -0.65% on Thursday received approval from U.S. regulators for its drug to treat a form of late-stage lung-cancer.

16-May-2024 6:46 PM

FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor IMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and 14.3 Month Median Overall Survival in Pivotal DeLLphi-301 Study Amgen to Host Webcast Investor Call on May 20, 2024 at 1:00 p.m. PT THOUSAND OAKS, Calif.

16-May-2024 3:57 PM

FDA approves Amgen's treatment for most deadly form of lung cancer

The FDA cleared the Amgen drug, called Imdelltra, as a treatment for patients with advanced small-cell lung cancer.

16-May-2024 3:23 PM

US FDA approves Amgen drug for small cell lung cancer, Bloomberg reports

The U.S. Food and Drug Administration has granted accelerated approval to Amgen's tarlatamab, a targeted immunotherapy for treating adults with advanced small cell lung cancer that has worsened despite chemotherapy, Bloomberg News reported on Thursday.

16-May-2024 10:29 AM

The Best Dividend Stocks For A Dovish Fed

Remember when the Federal Reserve stopped printing money for a few months? It didn't go well.

16-May-2024 10:06 AM

Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.

15-May-2024 6:45 PM

AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024

THOUSAND OAKS, Calif. , May 15, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 1:00 p.m.

15-May-2024 1:03 PM

Trade Tracker: Joe Terranova buys Amgen and Merck

Joe Terranova, Senior Managing Director for Virtus Investment Partners, joins CNBC's "Halftime Report" to detail his latest buys